Patents Examined by Daniel R Carcanague
  • Inhibitors of Plasma Kallikrein and uses thereof
    Patent number: 11168083
    Abstract: Provided herein are compounds that inhibit pKal, a serine protease whose activity is responsible for proteolytically cleaving kininogen and generating the potent vasodilator and pro-inflammatory peptide bradykinin, which can lead to painful and debilitating inflammatory attacks (e.g., edema). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating pKal-related diseases and disorders (e.g., edema) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: November 9, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jeremy Travins, Thomas Miller, Nikolaos Papaioannou
  • 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
    Patent number: 11168073
    Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: November 9, 2021
    Assignee: YUHAN CORPORATION
    Inventors: Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Eui Chul Lee, Sol Park, Hyok Jun Cho, Cheol Hee Lim, So Young Kim, Hyun Ho Choi, Da Na Jeong, Na Yeon Yang, Na Ry Ha
  • Potassium channel inhibitors
    Patent number: 11168074
    Abstract: A compound of the general formula (I). The compounds of formula I are useful for treatment of a cardiac disease, disorder or condition in a mammal.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: November 9, 2021
    Assignee: ACESION PHARMA ApS
    Inventors: Ulrik Svane Sørensen, Antonio Mete
  • Tricyclic fused thiophene derivatives as JAK inhibitors
    Patent number: 11161855
    Abstract: The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: November 2, 2021
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Wenyu Zhu, Song Mei, Joseph Glenn
  • Chemical compounds as H—PGDS inhibitors
    Patent number: 11149035
    Abstract: A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoletic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: October 19, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DFVELOPMENT LIMITED
    Inventors: David Norman Deaton, Barry George Shearer, Mark Andrew Youngman
  • N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof
    Patent number: 11149021
    Abstract: An N-(azaaryl)cyclolactam-1-carboxamide derivative having a structure of formula (I), a preparation method therefor, and a use thereof are disclosed in the application. Each substituent are defined in the specification and claims. The series of compounds of the application can be widely applied in the preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease or metastatic disease, particularly for treating ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, primary tumor site metastasis or osseous metastasis cancer, and are expected to be developed into a new generation of CSF-1R inhibitor drugs.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: October 19, 2021
    Assignee: ABBISKO THERAPEUTICS CO., LTD.
    Inventors: Baowei Zhao, Mingming Zhang, Hongping Yu, Shuqun Yang, Zhui Chen, Yaochang Xu
  • 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor
    Patent number: 11149036
    Abstract: The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: October 19, 2021
    Assignees: MSD R&D (China) Co., Ltd., Merck Sharp & Dohme Corp.
    Inventors: John J. Acton, III, Jianming Bao, Qiaolin Deng, Melissa Egbertson, Ronald Ferguson, II, Xiaolei Gao, Scott Timothy Harrison, Sandra L. Knowles, Chunsing Li, Michael Man-Chu Lo, Robert D. Mazzola, Jr., Zhaoyang Meng, Meng Na, Michael T. Rudd, Oleg Selyutin, David M. Tellers, Ling Tong, Fengqi Zhang
  • LDHA activity inhibitors
    Patent number: 11142520
    Abstract: The invention provides compounds of formula (I), stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof: (I) wherein A1 to A6 and R1 to R4 are as defined herein. Such compounds are suitable for use in the treatment or prevention of diseases or conditions which are mediated by the activation of lactate dehydrogenase A (LDHA), for example cancer.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: October 12, 2021
    Assignee: ARCTIC PHARMA AS
    Inventors: Jo Klaveness, Bora Sieng, Steffi Lundvall, Claudia Alejandra Bøen, Kathrin Hnida
  • Kappa opioid receptor antagonists and products and methods related thereto
    Patent number: 11124504
    Abstract: Compounds are provided that antagonize the kappa-opioid receptor (KOR) and products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof: wherein X, Y, R1, R2, R4, R5 R6, R7, R8 and R11 are as defined herein.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: September 21, 2021
    Assignees: THE SCRIPPS RESEARCH INSTITUTE, BLACKTHORN THERAPEUTICS, INC.
    Inventors: Edward Roberts, Miguel A. Guerrero, Mariangela Urbano, Hugh Rosen, Robert M. Jones, Candace Mae Laxamana, Xianrui Zhao, Eric Douglas Turtle
  • Use for dyeing keratin fibers of a compound of azomethine type bearing a quinoline-derived unit
    Patent number: 11117864
    Abstract: The invention relates to a compound chosen from the compounds of formula (I) below, the optical and geometrical isomers thereof and the tautomers thereof, and also the addition salts thereof with an acid or a base, and the solvates thereof: (I). The invention also relates to the use of these particular compounds and the compositions for dyeing keratin fibers.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: September 14, 2021
    Assignee: L'OREAL
    Inventors: Stéphane Sabelle, Aziz Fadli
  • Substituted pyridinyl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
    Patent number: 11103493
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: August 31, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Hua Zhou, Xavier Fradera, Yongxin Han, Meredeth A. McGowan, Nunzio Sciammetta, Catherine White, Wensheng Yu
  • Pyrano[3,4-b]pyrazine kappa opioid receptor ligands for treating addiction, pruritus, pain, and inflammation
    Patent number: 11091497
    Abstract: 1-Phenylacetyl-8-aminohexahydro-2H-pyrano[3,4-b]pyrazines of formula are disclosed. The compounds are kappa ligands and are useful to treat drug dependency, pruritus, pain, and inflammation.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: August 17, 2021
    Assignee: The Rockefeller University
    Inventors: Mary Jeanne Kreek, Amy Ripka, Brian Reed, Eduardo Butelman
  • Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same
    Patent number: 11091479
    Abstract: The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: August 17, 2021
    Assignee: YUHAN CORPORATION
    Inventors: Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Dong Hoon Kim, Su Bin Choi, Sol Park, Hyun Ho Choi, Tae Wang Kim, Mi Kyeong Ju, Na Ry Ha
  • Tetrahydrate of H3 ligand, its process of preparation and pharmaceutical compositions comprising the same
    Patent number: 11078183
    Abstract: The present invention concerns the tetrahydrate form of the compound: (3S)-4-{4-[3-(3-methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide, dihydrochloride, its process of preparation and therapeutical uses thereof.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: August 3, 2021
    Assignee: BIOPROJET
    Inventors: Marc Capet, Jeanne-Marie Lecomte, Jean-Charles Schwartz
  • Photoresponsive nucleotide analog capable of photocrosslinking in visible light region
    Patent number: 11078211
    Abstract: Provided are a compound represented by the following formula I; a novel photoreactive compound that can be used in nucleic acid photoreaction techniques by a photoreactive crosslinking agent comprising the compound; and a photoreactive crosslinking agent in which the photoreactive compound is used.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: August 3, 2021
    Assignees: JAPAN ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY, NICCA CHEMICAL CO., LTD.
    Inventors: Takahiro Inatsugi, Ayako Koto, Isao Ishimaru, Masahiko Takamura, Kenzo Fujimoto
  • Rock-inhibiting compound and uses thereof
    Patent number: 11078161
    Abstract: Disclosed herein are a compound of formula (I) and a preparation method and uses thereof. The compound shows a good inhibitory activity against ROCK, providing a new medicinal strategy to clinically treat the diseases associated with abnormal ROCK activity.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: August 3, 2021
    Assignee: HITGEN INC.
    Inventors: Jin Li, Dengyou Zhang, Jingchao Feng, Wei Liao, Li Lin, Si Li
  • Poly(ADP-ribose) polymerase inhibitor, preparation method and use
    Patent number: 11072596
    Abstract: Disclosed are a compound as shown in general formula I, a pharmaceutically acceptable salt, an isomer or a mixture thereof, and a solvate, a polymorph, a stable isotope derivative or a prodrug thereof. The compound of the present disclosure has comparatively strong PARP inhibitory activity and can be used for treating diseases associated with PARP, such as cancers and inflammatory diseases.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: July 27, 2021
    Assignee: SELECTION BIOSCIENCE LLC
    Inventors: Fuyao Zhang, Hongshun Yuan, Xiaoming Shen
  • Potent antiviral pyrazolopyridine compounds
    Patent number: 11059817
    Abstract: The present technology provides compounds according to Formulas (I), (II), or (III) useful in inhibiting an enterovirus, paramyxovirus, respiratory virus, flaviviridae virus, bunyaviridae virus, togaviridae virus, or rabies virus in a cell and/or treating subjects suffering from an enterovirus, paramyxovirus, respiratory virus, flaviviridae virus, bunyaviridae virus, togaviridae virus, or rabies virus.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: July 13, 2021
    Assignee: The Regents of the University of California
    Inventors: Paul Krogstad, Michael E. Jung, Jun Zuo, Yanpeng Xing
  • Compositions and methods for intrathecal administration of MCOPPB for pain relief
    Patent number: 11045459
    Abstract: The invention provides compositions and methods for intrathecal administration of the compound MCOPPB or a pharmaceutically acceptable salt thereof for treating pain, such as neuropathic pain suffered by an adult human.
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: June 29, 2021
    Assignee: Centrexion Therapeutics Corporation
    Inventors: James N. Campbell, Barton Harley Manning
  • Melanin production inhibitor, whitening agent, fibroblast activator, collagen and/or elastin production promotor and wrinkle ameliorant
    Patent number: 11045471
    Abstract: The present invention provides an agent containing an orotic acid derivative that has high solubility in solvent and has superior physiological activity. The agent of the present invention is a melanin production inhibitor, whitening agent, fibroblast activator, collagen and/or elastin production promoter or wrinkle ameliorant containing as an active ingredient thereof an orotic acid derivative represented by the following general formula (1) or a salt thereof. In formula (1), R preferably represents a side chain of glutamic acid, glycine, histidine or aspartic acid. [In formula (1), R represents a side chain of a naturally-occurring amino acid and R may form, together with a nitrogen atom adjacent thereto through a single carbon atom, a hetero ring.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: June 29, 2021
    Assignee: SHOWA DENKO K.K.
    Inventors: Daisuke Yagyu, Yuko Nakagami, Ryota Niibayashi, Eiko Kato